<DOC>
	<DOCNO>NCT00100854</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Estrogen cause growth non-small cell lung cancer cell . Hormone therapy use fulvestrant may fight non-small cell lung cancer lower amount estrogen body make . Giving erlotinib together fulvestrant may kill tumor cell . It yet know whether give erlotinib together fulvestrant effective erlotinib alone treat non-small cell lung cancer . PURPOSE : This randomized phase II trial study give erlotinib together fulvestrant see well work compare erlotinib alone treat patient stage IIIB stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib With Without Fulvestrant Treating Patients With Stage IIIB Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare objective tumor response patient stage IIIB IV non-small cell lung cancer treat erlotinib hydrochloride v without fulvestrant . Secondary - Correlate response rate ER EGF receptor expression patient treat regimen . - Correlate measurement ER-α , ER-β , EGF/HER-1 receptor HER-2/neu receptor clinical response patient treat regimen . - Correlate erlotinib hydrochloride resistance ER HER receptor expression patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord performance status , gender , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral erlotinib hydrochloride daily day 1-28 . Courses repeat every 28 day . - Arm II : Patients receive erlotinib hydrochloride arm I fulvestrant intramuscularly day 1 , 15 , 29 , every 28 day thereafter . In arm , treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 2 month disease progression . PROJECTED ACCRUAL : A total 102 patient ( 34 arm I 68 arm II ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Inclusion criterion : adult age 18 capable give informed consent . Histologically confirm nonsmall cell lung cancer Stage IIIB IV NSCLC Tumor tissue block available . ECOG performance status 0 , 1 2 . Measurable disease RECIST criterion define ≥ 1 target lesion irradiate . New lesion develop previously irradiate field may use site measurable disease provide criterion meet . Meets 1 follow criterion : Progressive disease ≥ 1 prior standard chemotherapy regimen Refused chemotherapy Unable receive standard chemotherapy woman childbearing age must negative pregnancy test urine serum prior initiation treatment . men woman childbearing potential must consent use adequate contraception throughout treatment 3 month follow surgery . Exclusion criterion : Renal insufficiency ( serum creatinine &gt; 2mg/dl ) Liver insufficiency ( serum total bilirubin &gt; 1.5X ULN , serum transaminase &gt; 2.5X ULN % X ULN hepatic metastasis ) . hematologic abnormality platelet &lt; 100,000 ANC &lt; 1,500/mm3 THerapeutic anticoagulation allow , patient receive fulvestrant therapeutic anticoagulation fulvestrant dose divide twice many syrinx minimize volume intramuscular injection patient . In patient receive low molecular weight heparin fondaparinux , medication hold 12 hour fulvestrant injection possible . Active CNS metastasis . New York Heart Association class III IV cardiac disease myocardial infarction within past 12 month symptomatic ventricular arrhythmia symptomatic conduction abnormality evidence clinically active interstitial lung disease Patients asymptomatic chronic stable radiographic change eligible pregnant nursing inadequate contraception hypersensitivity erlotinib hydrochloride fulvestrant excipients comorbid disease medical condition would preclude study treatment compliance malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ cervix chemotherapy noncytotoxic investigational agent within 4 week initiate treatment . major surgery within 4 week initiate therapy . Minor surgery within 7 day initiate therapy . anticancer antiestrogen therapy . Concurrent stabledose steroid allow concomitant radiation therapy lung . Radiation therapy nontarget lesion allow long complete 1 week prior initiation treatment . prior anticancer epidermal growth factor receptor inhibitor concurrent CYP3A4 inducer , include follow : Phenytoin Carbamazepine Rifampin Barbiturates Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>